Search Results 771-780 of 18366 for alopecia

1. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Patients with Solid Tumors - Mayo Clinic

   Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1 (except for alopecia). Known human immunodeficiency virus (HIV) ...

2. Study of bb2121 in Multiple Myeloma - Clinical Trials

   Recovery to ≤ Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy. * True abstinence ...

3. A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician’s choice chemotherapy, for the treatment of participants with metastatic HER2-positive breast cancer - Mayo Clinic

   Alopecia; Neuropathy resolved to ≤ Grade 2; Congestive heart failure that was ≤ Grade 1 in severity at the time of occurrence and resolved completely. Has ...

4. Rem-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS - Mayo Clinic

   Note: Stable chronic and clinically nonsignificant conditions (≤ Grade 2) that are not expected to resolve (eg, neuropathy, myalgia, alopecia, prior ...

5. Study of TJ011133 in Participants With Relapsed/ Refractory Advanced Solid Tumors and Lymphoma - Mayo Clinic

   Not recovered (i.e., to ≤ Grade 1 or to baseline) from AEs emerging from previous treatments (except alopecia or neuropathy). Incomplete recovery from AEs ...

6. A Study of Unesbulin Combined with Dacarbazine to Treat Advanced Leiomyosarcoma (LMS) - Mayo Clinic

   Toxicity from prior therapies recovered to Grade ≤ 1 or subject's baseline, except for alopecia. In addition, endocrinopathies associated with prior ...

7. A Study to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors - Mayo Clinic

   ... alopecia, vitiligo). Participants with Grade 2 toxicities that are deemed stable or irreversible (e.g., chemotherapy related arthritis or tendinitis, skin ...

8. A Study to Evaluate AMG 701 in Subjects with Multiple Myeloma - Mayo Clinic

   ... alopecia or toxicities from prior anticancer therapy that are considered irreversible (defined as having been present and stable for > 4 weeks) which may be ...

9. A Study to Evaluate Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for Multiple Myeloma with Minimal Residual Disease (MRD) to Direct Therapy Duration - Mayo Clinic

   All ASCT-related toxicities must have recovered to ≤ Grade 1 (except for alopecia, fatigue and amenorrhea) prior to first randomization. Mucositis and ...

10. Celebrations during a pandemic - Mayo Clinic

    There's still time! ... Hurry to 3X your gift's impact on cancer research and care! Triple My Impact.